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Abstract
Background: The last case of poliomyelitis due to transmission of indigenous wild poliovirus occurred in
Italy in 1982, however, it is important to guarantee a high quality surveillance as there is a risk of
importation of cases from areas where polio is endemic. Stopping poliovirus transmission is pursued
through a combination of high infant immunization coverage and surveillance for wild poliovirus through
reporting and laboratory testing of all cases of acute flaccid paralysis (AFP) among children under fifteen
years of age. The aim of this study was to describe and to evaluate 11 years of active surveillance in the
Marches (Italy) in terms of: incidence, aetiology and clinical manifestation of AFP cases.
Methods: The active Acute Flaccid Paralysis surveillance has been carried out in the Marches region since
February 1997 by the Chair of Hygiene which established a regional hospital network. Active surveillance
involves 15 hospital centres.
Results: In the considered period, 0–15 years population varied between 187,051 in 1997 to 201,625 in
2007, so the number of AFP expected cases is 2 per year. From February 1997 to October 2007, 27 cases
were found with rates of 1.0/100,000 in 1997; 2.0/100,000 in 1998; 1.0/100,000 in 1999; 0.5/100,000 in
2000; 2.5/100,000 in 2001; 1.0/100,000 in 2002; 0 in 2003; 0.5/100,000 in 2004; 1.5/100,000 in 2005; 2.0/
100,000 in 2006; 1.5/100,000 in 2007. In 29.6% of cases two stool samples were collected in 14 days from
the symptoms onset. The 60-days follow-up is available for 23 out of 27 cases reported. In 44.5% of cases
the definite diagnosis was Guillain Barrè syndrome.
Conclusion: In general, the surveillance activity is satisfactory even if in presence of some criticalities in
biological samples collection. The continuation of surveillance, in addition to the maintenance of current
levels of performance, will tend to a further and more detailed sensitization of all workers involved, in
order to obtain spontaneous and prompt reporting, and to achieve the optimal standards recommended
by the WHO both in the collection of biological samples and the availability of 60 days follow-up, with the
goal of eradicating polio from all countries.
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Background
In May 1988, the World Health Assembly committed the
World Health Organization (WHO) to achieving the goal
of global eradication of poliomyelitis by the year 2000.
This goal is defined as:
￿ no cases of clinical poliomyelitis associated with wild
poliovirus, and
￿ no wild poliovirus found worldwide [1].
Europe has been poliofree since 2002, the last case of poli-
omyelitis due to transmission of indigenous wild poliovi-
rus occurred in Italy in 1982 [2,3]. Despite the problem of
poliomyelitis is not a priority, in poliofree countries, it is
important to guarantee a high quality surveillance as there
is a risk of importation of cases from areas where the dis-
ease is endemic. The year 2006 began with confirmation
that indigenous wild poliovirus transmission had been
stopped in Egypt and Niger, reducing the number of
endemic countries to a historic low of four (in 1988, wild
poliovirus was endemic in more than 125 countries). Four
countries had not interrupted indigenous transmission of
wild poliovirus: Afghanistan, India, Nigeria and Pakistan
and accounted for 94% of all new cases of poliomyelitis
in 2006. The remaining 6% of all new cases of poliomye-
litis occurred in countries into which poliovirus has been
reintroduced [4,5].
Poliomyelitis (Polio) is a highly infectious disease caused
by a virus. It invades the nervous system, and can cause
total paralysis in a matter of hours. It can strike at any age,
but affects mainly children under three (over 50% of all
cases). One in 200 infections leads to irreversible paralysis
(usually in the legs). Amongst those paralysed, 5–10% die
when their breathing muscles become immobilized.
Although polio paralysis is the most visible sign of polio
infection, fewer than 1% of polio infections ever result in
paralysis. Poliovirus can spread widely before cases of
paralysis are seen. Because of this silent transmission and
the rapid spread of poliovirus, WHO considers a single
confirmed case of polio paralysis to be evidence of an out-
break. There is no cure for polio, it can only be prevented
through immunization. Polio vaccine, given multiple
times, almost always protects a child for life. Full immu-
nization will markedly reduce an individual's risk of
developing paralytic polio. Polio is one of only a limited
number of diseases that can be eradicated, this is because
polio only affects humans, an effective vaccine is availa-
ble, and immunity is lifelong. [6,7] Stopping poliovirus
transmission has been pursued through a combination of
routine immunization and supplementary immunization
campaigns which are guided by high quality surveillance.
The four key strategies for stopping poliovirus transmis-
sion are:
1. High infant immunization coverage with four doses of
oral polio vaccine (OPV) in the first year of life, WHO has
established a global target of at least 90% immunization
coverage for all vaccines used in the Expanded Programme
on Immunization, including oral polio vaccine, by the
year 2000. In Italy, since 2002 polio immunization sched-
ule has been changed from two doses of OPV and two of
IPV to 4 doses of the last one, OPV has been excluded.
2. National immunization days (NIDs): this is a supple-
mentary immunization which is intended to comple-
ment, not replace, routine immunization. The aim of
mass campaigns is to interrupt circulation of poliovirus by
immunizing every child under 5 years of age with two
doses of OPV, regardless of previous immunization status.
3. Surveillance for wild poliovirus through reporting and
laboratory testing of all cases of acute flaccid paralysis
(AFP) among children under fifteen years of age. The
number of cases reported each year is used as an indicator
of a country's ability to detect polio, even in countries
where the disease no longer occurs. A country's surveil-
lance system should be sensitive enough to detect at least
1 case of AFP for every 100,000 children under 15, even in
the absence of polio and if are tested ≥ 80% of stool spec-
imens.
4. Targeted "mop-up" campaigns are implemented in a
country when the final pockets of poliovirus transmission
have been identified with certification-standard surveil-
lance. The campaigns involve door-to-door immuniza-
tion in high-risk districts where the virus is known or
suspected to still be circulating.
AFP case was defined as a child aged less than 15 years
showing acute onset of flaccid paralysis in one or more
limbs, or acute onset of bulbar paralysis [8,2]. The differ-
ential diagnosis of acute flaccid paralysis includes para-
lytic poliomyelitis, Guillain-Barré syndrome and
transverse myelitis; less common aetiologies are traumatic
neuritis, encephalitis, meningitis and tumours. Distin-
guishing characteristics of paralytic polio are: asymmetric
flaccid paralysis, fever at onset, rapid progression of paral-
ysis, residual paralysis after 60 days, and preservation of
sensory nerve function [7-9].
The aim of this study was to describe and to evaluate 11
years of active surveillance in the Marches (Italy) in terms
of: incidence, aetiology and clinical manifestation of AFP
cases.
Methods
Organization of AFP Surveillance in Italy
In January 1996, a program of active AFP surveillance with
a target population aged 0–15 was set-up as a pilot studyBMC Infectious Diseases 2008, 8:135 http://www.biomedcentral.com/1471-2334/8/135
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limited to four representative regions of Italy located in
different parts of the country. The surveillance, extended
to a national level in 1997, is conducted by the National
Institute of Health (ISS) and the Ministry of Health
(MOH) through reference laboratories, mainly University
Laboratories of Hygiene, located in each of the 20 Italian
regions. Local networks of collaborating hospitals (Paedi-
atrics, Neurology and Infectious Disease Wards) were
directly coordinated by the person in charge of the
Regional Reference Centre (RRC).
Every case of AFP in the 0–15 years population has to be
notified to ISS and MOH by the RRC through a prelimi-
nary questionnaire with clinical and epidemiological
information.
Clinical samples for virological investigation are collected
for each case and consist of: two stool specimens taken
24–48 hours apart and one serum sample, within 14 days
since the onset of paralysis, samples are appropriately
placed in refrigerated container for transport. Laboratory
analysis consists of the evaluation of viral growth after two
blind passages on cells lines (RD and L20B) sensitive to
poliovirus (3 serotypes) infection and non polio enterovi-
rus (Coxsackie virus A; Coxsackie virus B1, B2, B3, B6; Echo-
virus; Enterovirus 70, 71) infection. Negativity refers to the
absence of viral growth.
All tests were carried out according to the standard proto-
cols recommended by WHO.
Serum samples are tested only if stool specimens are
potentially infectious for poliovirus. After the notifica-
tion, a follow-up questionnaire with more detailed infor-
mation has to be sent to ISS and MOH to determine
whether there is residual paralysis or death at 60 days after
diagnosis, and to clarify the final diagnosis (card concern-
ing the case containing information about clinical, instru-
mental and laboratory examinations).
Cases are classified based on clinical and laboratory infor-
mation, in:
1. poliomyelitis: poliovirus identified in the stool speci-
men;
2. non polio: cases without poliovirus in stool specimens
and no residual paralysis at 60 days;
3. polio compatible: cases not definitely classified as non-
polio on the available information. Acute disease with
residual paralysis after 60 days or death or loss of the sub-
ject during follow-up, in which it was not possible to col-
lect at least 2 stool samples within 14 days from the onset
of paralytic symptoms;
4.  vaccine-associated paralytic poliomyelitis (VAPP):
paralytic disease caused by vaccination with OPV. The
association is thought to be valid if the vaccine is admin-
istered at the same subject in a period of time from 4 to 30
days before the onset of symptoms. As for contacts a
period of 4–75 days must be considered. In patients with
immunodeficiency the period may be longer than 30 days
for recipients cases and longer than 75 days for the contact
cases [10].
Organization of AFP Surveillance in the Marches Region
The Chair of Hygiene at the Università Politecnica of the
Marche, a reference Centre for Marche region, has started
the surveillance of acute flaccid paralysis in February 1997
realizing a network of 15 hospital centres, placed in the 4
provinces of the Marche. One or more references have
been identified in each hospital centre. Every 15–20 days
all reference doctors of the 25 Operative Units (15 of Pae-
diatrics, 3 of Infectious Diseases, 7 of Neurology/Child
Neuropsychiatry) belonging to the network are contacted
by phone. For every case of AFP the management is acti-
vated according to the directives of ISS and MOH.
This surveillance did not expect the authorization from a
local Ethics Committee as it is a national ministerial
project taking into account the WHO directives for the
achievement of the poliomyelitis eradication (WHA 41.28
of May 1988). This work has been realised in part thanks
to the financial contribution of the research project "Pre-
vention of risk factors of the mother-child health". Art 12
D.L.vo. 502/1992, research line 4.4, "Study of flaccid
paralysis in Italy". Stool and serum samples are collected
form children suffering from acute flaccid paralysis sub-
ject to parents or a legal guardian agreement taken by a
doctor of the department. This consensus is included in
the medical record of every patient. Research carried out
on humans was performed in compliance with the Hel-
sinki Declaration.
Results and discussion
In the Marche Region 0–15 years population varied from
187,051 in 1997 to 201,625 in 2007, so the number of
AFP expected cases is 2 per year.
Between February 1997 and December 2007, 27 cases
were reported (Figure 1), with rates of 1.0/100,000 in
1997; 2.0/100,000 in 1998; 1.0/100,000 in 1999; 0.5/
100,000 in 2000; 2.5/100,000 in 2001; 1.0/100,000 in
2002; 0 in 2003; 0.5/100,000 in 2004; 1.5/100,000 in
2005; 2.0/100,000 in 2006; 1.5/100,000 in 2007.
The mean age of AFP cases was 7 years (SD, ± 4 years):
37% of cases were less 5 years of age, 37% between 5 and
10 years and 26% between 10 and 15 years. There is a sim-
ilar proportion of AFP cases by sex: 15 in males and 12 in
females.BMC Infectious Diseases 2008, 8:135 http://www.biomedcentral.com/1471-2334/8/135
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The distribution by month is characteristic, with 70.4% of
cases notified between May and October.
Considering the Province of residence of cases, these are
distributed with a percentage of 59.3% in the south of the
Region. 44.4% of case reports comes from the High Spe-
cialized Hospital "G Salesi" (Child Neuropsychiatry, Pae-
diatrics and Paediatric Intensive Care Units).
The final diagnosis of AFP in the 27 reported cases is
shown in table 1. No case of poliomyelitis and vaccine-
associated paralytic poliomyelitis was identified. Guillain-
Barrè syndrome (GBS) was the most common diagnosis
(44.5%), followed by polyradiculoneuritis (7.4%),
encephalomyelitis/myelitis (18.5%), 1 case immunitary
multineuropathy, 1 case by synovial cyst compression.
Cases with residual disabilities at 60 days were 7 out of 23.
In two cases no diagnostic definition was found (but a
60–90 days follow up permitted to exclude paralysis);
four cases were lost to follow up, one faecal specimen was
analysed for each of these cases, with no poliovirus isola-
tion. One of these cases was classified as non polio by the
MOH on the basis of medical records."
All patients showed serious motor deficiency due to para-
lytic involvement of the limbs; in 7 cases at the beginning
of the paralysis was present fever, 17 cases showed the
progression of paralysis within 4 days from the onset of
symptoms, in 19 cases paralysis was symmetric and in 4
cases occurred a respiratory paralysis.
At follow-up, that was performed after 60–90 days from
the onset of paralytic symptoms, 4 cases were lost. In 16/
23 cases was found a normal resumption of walking
about, while in 7/23 were reported some disabilities as for
example limb and goose like walk. Three cases of AFP
Distribution of AFP Cases in the Marches Region (from February 1997 to December 2007) Figure 1
Distribution of AFP cases in the Marches region (from February 1997 to December 2007).
Table 1: Final classification in 27 cases of AFP (from February 
1997 to December 2007).
Final classification No. cases (%)
Guillain-Barrè syndrome 12
Encephalomyelitis/myelitis 5
Polyradiculuneuritis 2
Synovial cyst compression 1
Immunitary multineuropaty 1
Lost during follow up 4
No diagnostic definition 2BMC Infectious Diseases 2008, 8:135 http://www.biomedcentral.com/1471-2334/8/135
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were also reported in outpatients: two from other Italian
regions and one from Germany. The only case reported in
the year 2000 was related to a case of AFP reported by a
Primary Care Paediatrician. One case of 2007 was
reported from a Paediatric Hospital of another Italian
Region.
As for laboratory tests, in general stool samples were col-
lected in 77.8% cases. Only one stool sample was col-
lected in 5/21 cases and two stool samples were collected
from 16/21 cases.
All faecal specimens analyzed by the reference laboratory
(National Institute of Health, Rome) resulted negative for
poliovirus. As reported in Table 2, the surveillance index,
that is the product between case incidence and percentage
of cases with a stool sample within 14 days from the
symptoms onset, has had a variable course, and meeting
the WHO target (= 80%) in 2002 only. In Table 2 are
showed some quality indicators of the surveillance and
the results reported.
In our experience, the AFP incidence rate in the 0–15 years
old population, was in general quite satisfactory.
The result obtained means that a quite good active surveil-
lance was performed, even if with minimal yearly fluctua-
tions in the number of cases identified. As for
geographical distribution of the reporting sites, was found
a predictable higher concentration of reports from the
Highly Specialized Hospital "G. Salesi", as it is a reference
hospital for children's diseases. The other reports, coming
from hinterland structures of the Marche, show also a sat-
isfying sensitization of all workers involved, that on sev-
eral occasions actively reported the cases, anticipating the
phone contact and reporting also cases managed in outpa-
tients setting by Primary Care Paediatricians.
As for gender of reported cases (substantial equivalence
between males and females) and distribution for age class
(frequency slightly higher in age class 0–5 y.o.) it was not
possible to make any epidemiological consideration due
to the few data available. Temporal distribution of cases is
rather characteristic, as most cases were concentrated in
the period May-October, this situation could be related to
the epidemiological progress of enterovirus infections,
that in temperate climate countries spread mainly during
summer and autumn. [11]
In most cases the following clinical conditions as Guil-
lain-Barrè, Syndrome, encephalitis/meningoencephalitis
and polyradiculoneuritis and other conditions are the
cause of the reported flaccid paralysis [2,12]. These find-
ings are in line with the diagnostic classification of overall
reported cases internationally and nationally.
With reference to surveillance quality indicators (Table 2)
some criticalities emerge compared to the values recom-
mended by the WHO and the ISS.
Table 2: Quality surveillance indicators of the AFP in the Marches (from February 1997 to December 2007).
INDICATORS 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Incidence rate (reported cases/expected cases) 1
2/2
2
4/2
1
2/2
0.5
1/2
2.5
5/2
1
2/2
-
0/2
0.5
1/2
1.5
3/2
2
4/2
1.5
3/2
% AFP cases with follow-up at 60–90 days from report 100 75 50 100 100 100 - 100 100 75* 67
% AFP cases with initial clinical classification 100 100 100 0 100 100 - 100 100 100 100
% AFP cases with final clinical classification 100 75 0 0 100 50 - 100 100 75 67
% AFP cases with 1 stool sample within 14 days 0 50 50 0 20 100 - 0 33 25 67
% AFP cases with 2 stool samples within 14 days 0 50 50 0 0 100 - 0 33 25 33
% AFP with 2 stool samples at any time 0 75 100 0 60 100 - 0 67 75 33
% AFP with 1 stool sample at any time 50 25 0 0 20 0 - 0 0 0 67
% AFP 0 stool sample 50 0 0 100 20 0 - 100 33 25 0
SURVEILLANCE INDEX incidence X 
(% AFP cases with a sample within 14 days)
0 1 0.5 0 0.5 1 - 0 0.5 0.5 1
* missing follow-up is referred to one case archived as non-polio by the MOH after clinical charts review.BMC Infectious Diseases 2008, 8:135 http://www.biomedcentral.com/1471-2334/8/135
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The target recommended by the WHO is to obtain a per-
centage of AFP cases with two stool samples, collected
within 14 days from the onset of symptoms, equal or
higher than 80%. In Marche Region this target was
achieved only in 2002; but considering the collection of
two samples at any time the performance is better.
The percentage of cases with follow-up at 60–90 days is
good as it is equal to 100 in 6 out of 11 years; this implies
a good percentage of final clinical diagnosis.
Although emphasizing the importance of active surveil-
lance of AFP cases, to the light of the above criticisms com-
plementary forms of surveillance must be taken into
consideration to achieve a more stable and rigorous polio
eradication. First of all immunization status and vaccina-
tion coverage of indigenous and emigrants must be sur-
veilled, moreover considering that Italy is a borderline
country. In fact, a gap in immunization status [13] or the
presence of parts of population not immunized [14]
together with the circulation of wild poliovirus, may led
to outbreaks. Italy is exposed to the risk of introduction of
polio virus, because of the arrival of people from countries
in which polio is still endemic. To overcome this risk, our
Region has been involved from January 2008, in the
National project "Surveillance of immunization status for
polio of people 0–14 years" with the aim of evaluating the
impact of the introduction of the IPV only vaccination
schedule in order to assess vaccination coverage and pro-
portion of people with antibodies titer against polio > 1/
8. Polio outbreak can be caused by circulating vaccine
derived poliovirus, as those reported in Egypt [15], Hispa-
niola [16] and Philippines [17] so, also if the OPV has
been discontinued in Italy, people from foreign countries
might contribute to the spread of these viruses, in these
cases environmental surveillance of polio virus might be
the key to its control.
Isolation of wild-type polioviruses from sewage samples
has been shown to reflect its circulation in the community
both qualitatively and quantitatively and has been used
for evaluation of the effectiveness of immunization or for
epidemiological investigations, in addition, such surveil-
lance can be used to monitor the circulation of vaccine-
derived polioviruses. [18] The possible implications of
poliovirus capsid recombination events for the generation
of potentially dangerous vaccine-derived strains are not
clear at present. [19]
Italian National Institute of Health is currently participat-
ing in the WHO study with the aim of typing and charac-
terizing of polioviruses and other enteroviruses isolated
from healthy children, immunodeficient subjects and
environmental samples" in six Italian cities (Palermo,
Bari, Roma, Sassari, Parma e Milano). [20]
Conclusion
In conclusion, AFP surveillance remains the gold standard
of poliovirus surveillance and all efforts should be made
to maintain it at high level of performance and improve it
when necessary [11]. The continuation of surveillance, in
addition to the maintenance of current levels of perform-
ance, will tend to a further and more detailed sensitization
of all workers involved, in order to obtain spontaneous
and prompt reporting, and to achieve the optimal stand-
ards recommended by the WHO also in the collection of
biological samples, with the goal of eradicating polio
from all countries. Other strategies to eradicate polio are
needed, our Region is currently participating in the Italian
MOH project for surveillance of immunization status i the
0–14 years population, environmental surveillance is not
currently performed in our Region.
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